Chimeric Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Rebecca McQualter
Chief executive officer
AU$453.9k
Total compensation
| CEO salary percentage | 11.0% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$454k | AU$50k | -AU$13m |
Compensation vs Market: Rebecca's total compensation ($USD282.04K) is about average for companies of similar size in the Australian market ($USD283.36K).
Compensation vs Earnings: Insufficient data to compare Rebecca's compensation with company performance.
CEO
Rebecca McQualter
less than a year
Tenure
AU$453,860
Compensation
Dr. Rebecca McQualter is Chief Executive Officer of Chimeric Therapeutics Limited from December 2024 and served as its Chief Operating Officer since May 1, 2024 until December 2024. Rebecca brings senior e...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5yrs | AU$301.98k | 20.43% A$ 1.2m | |
| Chief Executive Officer | less than a year | AU$453.86k | no data | |
| CFO, Joint Company Secretary & Director | 4.3yrs | no data | 1.04% A$ 62.0k | |
| Chief Technology Officer | no data | AU$1.16m | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Joint Company Secretary | 4.3yrs | no data | no data |
4.3yrs
Average Tenure
63.5yo
Average Age
Experienced Management: CHM's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5yrs | AU$301.98k | 20.43% A$ 1.2m | |
| CFO, Joint Company Secretary & Director | 1.6yrs | no data | 1.04% A$ 62.0k | |
| Member of Glioblastoma Expert Advisory Board | no data | no data | no data | |
| Non-Executive Director | 1.5yrs | AU$68.78k | no data | |
| Non-Executive Director | 4.5yrs | AU$50.00k | 0.17% A$ 10.4k | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Glioblastoma Expert Advisory Board | no data | no data | no data | |
| Member of Glioblastoma Expert Advisory Board | 4.1yrs | no data | no data | |
| Chairman of Glioblastoma Expert Advisory Board | no data | no data | 1.22% A$ 73.0k | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 3.5yrs | no data | no data | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 3.4yrs | no data | no data |
3.4yrs
Average Tenure
65yo
Average Age
Experienced Board: CHM's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 05:47 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chimeric Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Maxim Jacobs | Edison Investment Research |
| null null | Lodge Partners Pty Ltd. |